{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:03:41Z","timestamp":1784819021258,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["SWU-KQ24032"],"award-info":[{"award-number":["SWU-KQ24032"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["XDJK2020RC001"],"award-info":[{"award-number":["XDJK2020RC001"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Venture & Innovation Support Program for Chongqing Overseas Re-turnees","award":["cx2019097"],"award-info":[{"award-number":["cx2019097"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Vet Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Porcine Respiratory Coronavirus (PRCV) is a genetic variant of Transmissible Gastroenteritis Virus (TGEV). It is only pathogenic to the respiratory tract, mainly manifesting as atypical interstitial pneumonia and mild subclinical symptoms. In addition, PRCV can also serve as a potential animal respiratory coronavirus model for the study of human respiratory coronaviruses. Developing effective PRCV antagonists is of great significance for the prevention and control of this disease. In this study, we found that Ursodeoxycholic acid (UDCA) can significantly inhibit the infection of PRCV in Porcine respiratory epithelial cells (NPTR). Further studies have shown that UDCA inhibits PRCV mainly through two mechanisms: First, UDCA can directly disrupt the components of the viral envelope and induce the disintegration of viral structure; Second, UDCA can significantly promote the secretion of IFN-\u03b2 in NPTR cells, enhance the phosphorylation and nuclear translocation of STAT1, and up-regulate the expression of the interferon-stimulated genes ISG15 and MX1. Molecular dynamics simulations showed that UDCA can be embedded into the hydrophobic pocket of the TLR4 dimerization domain, thereby activating the TLR4-IRF3 signaling pathway, inducing the production of IFN-\u03b2, and inhibiting PRCV infection. Schaftoside, an inhibitor of the TLR4 signaling pathway, can effectively reverse the anti-PRCV activity of UDCA. Finally, an ex vivo lung tissue slice model of piglets was established to verify that UDCA can effectively reduce the PRCV viral load and inflammatory response in lung tissues. The results of this study provide a scientific basis for the development of antiviral drugs against PRCV and offer new insights into the research on human respiratory coronaviruses.<\/jats:p>","DOI":"10.1186\/s13567-026-01721-1","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T19:53:55Z","timestamp":1772481235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ursodeoxycholic acid inhibits pneumonia caused by PRCV through the activation of TLR4-IRF3 mediated type \u2160 interferon pathway"],"prefix":"10.1186","volume":"57","author":[{"given":"Xingcui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinman","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"1721_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","volume":"1282","author":"AR Fehr","year":"2015","unstructured":"Fehr AR, Perlman S (2015) Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 1282:1\u201323","journal-title":"Methods Mol Biol"},{"key":"1721_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/01652176.1986.9694050","volume":"8","author":"M Pensaert","year":"1986","unstructured":"Pensaert M, Callebaut P, Vergote J (1986) Isolation of a porcine respiratory, non-enteric coronavirus related to transmissible gastroenteritis. Vet Q 8:257\u2013261","journal-title":"Vet Q"},{"key":"1721_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/v12040402","volume":"12","author":"T Cui","year":"2020","unstructured":"Cui T, Theuns S, Xie J, Broeck WVD, Nauwynck HJ (2020) Role of porcine aminopeptidase N and sialic acids in porcine coronavirus infections in primary porcine enterocytes. Viruses 12:402","journal-title":"Viruses"},{"key":"1721_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu B, Guo H, Zhou P (2021) Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 19:141\u2013154","journal-title":"Nat Rev Microbiol"},{"key":"1721_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1517\/14728214.2016.1150999","volume":"21","author":"AH Ali","year":"2016","unstructured":"Ali AH, Tabibian JH, Carey EJ, Lindor KD (2016) Emerging drugs for the treatment of primary biliary cholangitis. Expert Opin Emerg Drugs 21:39\u201356","journal-title":"Expert Opin Emerg Drugs"},{"key":"1721_CR6","first-page":"610","volume":"25","author":"A Daruich","year":"2019","unstructured":"Daruich A, Picard E, Boatright JH (2019) Review: the bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease. Mol Vis 25:610\u2013624","journal-title":"Mol Vis"},{"key":"1721_CR7","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/cmdc.201300059","volume":"8","author":"PI Dosa","year":"2013","unstructured":"Dosa PI, Ward T, Castro RE, Rodrigues CMP, Steer CJ (2013) Synthesis and evaluation of water-soluble prodrugs of ursodeoxycholic acid (UDCA), an anti-apoptotic bile acid. ChemMedChem 8:1002\u20131011","journal-title":"ChemMedChem"},{"key":"1721_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194839","volume":"13","author":"AA Shaheen","year":"2018","unstructured":"Shaheen AA, Kaplan GG, Almishri W (2018) The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes. PLoS One 13:e0194839","journal-title":"PLoS One"},{"key":"1721_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00042737-200502000-00001","volume":"17","author":"S Bellentani","year":"2005","unstructured":"Bellentani S (2005) Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go? Eur J Gastroenterol Hepatol 17:137\u2013140","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1721_CR10","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1194\/jlr.R049437","volume":"55","author":"AF Hofmann","year":"2014","unstructured":"Hofmann AF, Hagey LR (2014) Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J Lipid Res 55:1553\u20131595","journal-title":"J Lipid Res"},{"key":"1721_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2024.113904","volume":"238","author":"WY Zhou","year":"2024","unstructured":"Zhou WY, Yang XR, Yin YR, Chen S, Yang LX, Li T, Liu J, Lu BH, Yang ZY, Li R, Zhang MM (2024) Ursodeoxycholic acid loaded dual-modified graphene oxide nanocomposite alleviates cholestatic liver injury through inhibiting hepatocyte apoptosis. Colloids Surf B Biointerfaces 238:113904","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1721_CR12","first-page":"11805","volume":"10","author":"FY Wang","year":"2017","unstructured":"Wang FY, Qin CY, Li Y, Qu WD, Liu H, Li B, Qi JN, Liu J, Wang LY (2017) Ursodeoxycholic acid induces autophagy via LC3B to suppress hepatocellular carcinoma in vivo and in vitro. Int J Clin Exp Pathol 10:11805\u201311813","journal-title":"Int J Clin Exp Pathol"},{"key":"1721_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41586-022-05594-0","volume":"615","author":"T Brevini","year":"2023","unstructured":"Brevini T, Maes M, Webb GJ et al (2023) FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature 615:134\u2013142","journal-title":"Nature"},{"key":"1721_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113021","volume":"150","author":"PX Thuy","year":"2022","unstructured":"Thuy PX, Bao TDD, Moon EY (2022) Ursodeoxycholic acid ameliorates cell migration retarded by the SARS-CoV-2 spike protein in BEAS-2B human bronchial epithelial cells. Biomed Pharmacother 150:113021","journal-title":"Biomed Pharmacother"},{"key":"1721_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0304-3835(99)00251-7","volume":"146","author":"DK Kim","year":"1999","unstructured":"Kim DK, Lee JR, Kim A, Lee S, Yoo MA, Kim KW, Kim ND, Suh H (1999) Inhibition of initiation of simian virus 40 DNA replication in vitro by the ursodeoxycholic acid and its derivatives. Cancer Lett 146:147\u2013153","journal-title":"Cancer Lett"},{"key":"1721_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01853","volume":"9","author":"S Fiorucci","year":"2018","unstructured":"Fiorucci S, Biagioli M, Zampella A, Distrutti E (2018) Bile acids activated receptors regulate innate immunity. Front Immunol 9:1853","journal-title":"Front Immunol"},{"key":"1721_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41564-019-0602-7","volume":"5","author":"KR Grau","year":"2020","unstructured":"Grau KR, Zhu S, Peterson ST, Helm EW, Philip D, Phillips M, Hernandez A, Turula H, Frasse P, Graziano VR, Wilen CB, Wobus CE, Baldridge MT, Karst SM (2020) The intestinal regionalization of acute norovirus infection is regulated by the microbiota via bile acid-mediated priming of type III interferon. Nat Microbiol 5:84\u201392","journal-title":"Nat Microbiol"},{"key":"1721_CR18","doi-asserted-by":"publisher","first-page":"12570","DOI":"10.1128\/JVI.05839-11","volume":"85","author":"Y Kim","year":"2011","unstructured":"Kim Y, Chang KO (2011) Inhibitory effects of bile acids and synthetic farnesoid X receptor agonists on rotavirus replication. J Virol 85:12570\u201312577","journal-title":"J Virol"},{"key":"1721_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2021.109097","volume":"257","author":"FZ Kong","year":"2021","unstructured":"Kong FZ, Niu XY, Liu MD, Wang QH (2021) Bile acids LCA and CDCA inhibited porcine deltacoronavirus replication in vitro. Vet Microbiol 257:109097","journal-title":"Vet Microbiol"},{"key":"1721_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41422-018-0136-1","volume":"29","author":"MM Hu","year":"2019","unstructured":"Hu MM, He WR, Gao P, Yang Q, He K, Cao LB, Li S, Feng YQ, Shu HB (2019) Virus-induced accumulation of intracellular bile acids activates the TGR5-\u03b2-arrestin-SRC axis to enable innate antiviral immunity. Cell Res 29:193\u2013205","journal-title":"Cell Res"},{"key":"1721_CR21","first-page":"1","volume":"44","author":"F Bessone","year":"2024","unstructured":"Bessone F, Hillotte GL, Ahumada N, Jaureguizahar F, Medeot AC, Roma MG (2024) UDCA for drug-induced liver disease: clinical and pathophysiological basis. Semin Liver Dis 44:1\u201322","journal-title":"Semin Liver Dis"},{"key":"1721_CR22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.bbi.2023.11.021","volume":"115","author":"F Zhang","year":"2024","unstructured":"Zhang F, Deng YT, Wang HD, Fu JX, Wu GY, Duan Z, Zhang XR, Cai YJ, Zhou HW, Yin J, He Y (2024) Gut microbiota-mediated ursodeoxycholic acids regulate the inflammation of microglia through TGR5 signaling after MCAO. Brain Behav Immun 115:667\u2013679","journal-title":"Brain Behav Immun"},{"key":"1721_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41586-022-05594-0","volume":"615","author":"T Brevini","year":"2023","unstructured":"Brevini T, Mase M, Webb GJ,\u00a0John BV, Fuchs CD, Buescher G, Wang L, Griffiths C, Brown ML, Scott WE 3rd, Pereyra-Gerber P, Gelson WTH, Brown S, Dillon S, Muraro D, Sharp J, Neary M, Box H, Tatham L, Stewart J, Curley P, Pertinez H, Forrest S, Mlcochova P, Varankar SS, Darvish-Damavandi M, Mulcahy VL, Kuc RE, Williams TL, Heslop JA, et al. (2023) FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature 615:134\u2013142","journal-title":"Nature"},{"key":"1721_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.15430\/JCP.2017.22.1.16","volume":"22","author":"WS Lee","year":"2017","unstructured":"Lee WS, Jung JH, Panchanathan R, Yun JW, Kim DH, Kim JK, Kim GS, Ryu CH, Shin SC, Hong SC, Choi YH, Jung JM (2017) Ursodeoxycholic acid induces death receptor-mediated apoptosis in prostate cancer cells. J Cancer Prev 22:16\u201321","journal-title":"J Cancer Prev"},{"key":"1721_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12081031","volume":"12","author":"G Rawal","year":"2023","unstructured":"Rawal G, Zhang JQ, Halbur PG, Gauger PC, Wang C, Opriessnig T (2023) Experimental infection of pigs with a traditional or a variant porcine respiratory coronavirus (PRCV) strain and impact on subsequent influenza A infection. Pathogens 12:1031","journal-title":"Pathogens"},{"key":"1721_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01355-20","volume":"58","author":"LJ Saif","year":"2020","unstructured":"Saif LJ, Jung K (2020) Comparative pathogenesis of Bovine and Porcine Respiratory Coronaviruses in the Animal Host Species and SARS-CoV-2 in Humans. J Clin Microbiol 58:e01355-20","journal-title":"J Clin Microbiol"},{"key":"1721_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147839","volume":"11","author":"J Chung","year":"2016","unstructured":"Chung J, An SH, Kang SW, Kwon K (2016) Ursodeoxycholic acid (UDCA) exerts anti-atherogenic effects by inhibiting RAGE signaling in diabetic atherosclerosis. PLoS One 11:e0147839","journal-title":"PLoS One"},{"key":"1721_CR28","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1128\/JVI.02190-07","volume":"82","author":"XS Zhang","year":"2008","unstructured":"Zhang XS, Alekseev K, Jung K, Vlasova A, Hadya N, Saif LJ (2008) Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome. J Virol 82:4420\u20134428","journal-title":"J Virol"},{"key":"1721_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.572885","volume":"8","author":"A Carino","year":"2020","unstructured":"Carino A, Moraca F, Fiorillo B, Marchiano S, Sepe V, Biagioli M, Finamore C, Bozza S, Francisci D, Distrutti E, Catalanotti B, Zampella A, Fiorucci S (2020) Hijacking SARS-CoV-2\/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on the receptor binding domain. Front Chem 8:572885","journal-title":"Front Chem"},{"key":"1721_CR30","doi-asserted-by":"publisher","first-page":"22288","DOI":"10.1038\/s41598-021-01705-5","volume":"11","author":"CFJ Rodal","year":"2021","unstructured":"Rodal CFJ, Perez MCL, Hernandez HMT, Sanchez NLM, Matias CCA, Martinez CM, Cruz PE, Zenteno E, Ramos MEG, Perez MEC, Romero CD, Perez CE (2021) Interaction of Spike protein and lipid membrane of SARS-CoV-2 with Ursodeoxycholic acid, an in-silico analysis. Sci Rep 11:22288","journal-title":"Sci Rep"},{"key":"1721_CR31","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1016\/j.apsb.2024.05.005","volume":"14","author":"X Liang","year":"2024","unstructured":"Liang X, Liu KP, Jia X, Cheng CQ, Zhang MQ, Kong LD, Li QQ, Liu Z, Li M, Li JL, Wang Y, Xu AL (2024) Suppressing FXR promotes antiviral effects of bile acids via enhancing the interferon transcription. Acta Pharm Sin B 14:3513\u20133527","journal-title":"Acta Pharm Sin B"},{"key":"1721_CR32","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","volume":"72","author":"DW Russell","year":"2003","unstructured":"Russell DW (2003) The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72:137\u2013174","journal-title":"Annu Rev Biochem"},{"key":"1721_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2174\/1874285800802010049","volume":"2","author":"A Xagorari","year":"2008","unstructured":"Xagorari A, Chlichlia K (2008) Toll-like receptors and viruses: induction of innate antiviral immune responses. Open Microbiol J 2:49\u201359","journal-title":"Open Microbiol J"}],"container-title":["Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13567-026-01721-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13567-026-01721-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13567-026-01721-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T13:19:10Z","timestamp":1775567950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13567-026-01721-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1721"],"URL":"https:\/\/doi.org\/10.1186\/s13567-026-01721-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8023786\/v1","asserted-by":"object"}]},"ISSN":["1297-9716"],"issn-type":[{"value":"1297-9716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}